Latest news
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) - Seeking AlphaSeeking Alpha · Tue, 04 Aug 2026 18:15:38 GMTAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 12:00:00 GMTExclusive BAC Article: Altimmune; Ph 3 MASH Study Initiation Pemvidutide Q3 2026, Positive AUD Data Leads To EOP2 Meeting, Additional Expansion Potential, And Catalysts (NASDAQ:ALT) - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 18:31:48 GMT